

Progress Report: Sri Lanka Clinical Trials Registry

SLCTR registration number: SLCTR/2022/013

Scientific title of trial: A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy and Safety of Sibeprenlimab Administered Subcutaneously in Subjects with Immunoglobulin A Nephropathy

Date of commencement (enrolment of first participant): 09 Dec 2022

Progression: 6 months ☐ 1 year ☐ 2 years ☐ 3 years ☐
4 years ☒

At completion ☐

1. Baseline data

Any changes to the trial design/ methodology/ protocol after commencement: Yes

Any changes to trial outcomes after commencement: No

2. Current status

Recruitment status: follow up continuing/ recruitment complete

Number assessed for eligibility:15

Number recruited and allocated/randomized:09

Number allocated/randomized to each intervention/arm (please edit as relevant):NA

Losses/exclusions after allocation/randomization (please edit as relevant):01

Consent withdrawals: 01

Early terminations: 00

3. Trial output

Date of trial completion ("last patient, last visit"): N/A

Final sample size: N/A

Summary of Interim/Final data (if available):

N/A

Abstract presentations of results at scientific meetings

Note: please include a URL link or scanned copy of the abstract

Title of Abstract	Full citation (please include authors, date, title of conference and place of presentation, page number of abstract).
N/A	

Publications

Note: please include a URL link or scanned copy of the publication

Title of paper	Full citation (please include authors, title of journal, volume, issue and page numbers, and/or DOI)
N/A	



.....
Name and signature of Responsible Registrant/
Principal Investigator: Prof. Eranga Wijewickrama

Date: 17 Jul 2026